A Plain Computed Tomography Scan is Sufficient to Consider Thrombolysis in Patients with Unknown Time of Onset
Stroke 44:1492-1493, Alexandrov, A., 2013
Computed Tomography Angiography in Hyperacute Ischemic Stroke
Stroke 44:1480-1488, Mortimer, A.,et al, 2013
Brain Abnormalities as an Initial Manifestation of Neuromyelitis Optica Spectrum Disorder
MSJ 17:1107-1112, Kim, W.,et al, 2013
Differential Diagnosis of Neuromyelitis Optica Spectrum Disorders
Brain Neurol 62:953-960, Tanaka, T., 2013
A Case-Controlled Comparison of Thrombolysis Outcomes Between Wake-Up and Known Time of Onset Ischemic Stroke Patients
Stroke 44:2226-2231, Manawadu, D.,et al, 2013
Thrombolysis of Basilar Artery Occlusion: Impact of Baseline Ischemia and Time
Ann Neurol 73:688-694, Strbian, D.,et al, 2013
An Observational Study of Thrombolysis Outcomes in Wake-Up Ischemic Stroke Patients
Stroke 44:427-431, Manawadu, D.,et al, 2013
Safety of Thrombolysis in Stroke Mimics
Stroke 44:1080-1084, Zinkstok, S.M.,et al, 2013
Autoimmune Chorea in Adults
Neurol 80:1133-1144, OToole, O.,et al, 2013
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
NEJM 368:914-923,952, Kidwell, C.S.,et al, 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Endovascular Treatment for Acute Ischemic Stroke
NEJM 368:914-923,952, Ciccone, A.,et al, 2013
Negative Diffusion-Weighted Imaging After Intravenous Tissue-Type Plasminogen Activator is Rare and Unlikely to Indicate Averted Infarction
Stroke 44-1629-1634, Freeman, J.,et al, 2013
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
Clinicopathologic Conferences, Celiac Disease, Addisons Disease, and Major Depression Disorder
NEJM 368:2015-2024, Case 16-2013, 2013
Diagnosis of Lambert-Eaton Myasthenic Syndrome in Children
Neurol 80:e220-e222, Morgan-Followell,B.& de los Reyes,E., 2013
Paediatric Autoimmune Encephalopathies: Clinical Features, Laboratory Investigations and Outcomes in Patients with or without Antibodies to known Central Nervous System Autoantigens
JNNP 84:748-755, Hacohen, Y.,et al, 2013
The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
Medicine 92:223-243, Rider, L.,et al, 2013
Results of Intravenous Thrombolysis within 4.5 to 6 Hours and Updated Results within 3 to 4.5 Hours of Onset of Acute Ischemic Stroke Recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR)
JAMA Neurol 70:837-844, Ahmed, N.,et al, 2013
Comparison of Final Infarct Volumes in Patients who Received Endovascular Therapy or Intravenous Thrombolysis for Acute Intracranial Large-Vessel Occlusions
JAMA Neurol 70:831-836, Rangaraju, S.,et al, 2013
Is Intra-Arterial Thrombolysis Beneficial for M2 Occlusions? Subgroup Analysis of the PROACT-II Trial
Stroke 44:240-242, Rahme, R.,et al, 2013
Density of Thrombus on Admission CT Predicts Revascularization Efficacy in Large Vessel Occlusion Acute Ischemic Stroke
Stroke 44:243-245, Moftakhar, P.,et al, 2013
Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies
Medicine 92:15-24, Fernandez, C.,et al, 2013
Prehospital Thrombolysis in Acute Stroke
Neurol 80:163-168, Weber, J.,et al, 2013
Central Nervous System Neuronal Surface Antibody Associated Syndromes: Review and Guidelines for Recognition
JNNP 83:638-645, Zuliani,L.,et al, 2012
Clinicopathologic Conference, Neurocysticercosis Involving the Cerebral Ventricles and Spinal Meninges
NEJM 366:1924-1934, Case 15-2012, 2012
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
Acute Stroke Imaging: What is Sufficient for Triage to Endovascular Therapies?
AJNR 33:790-792, Lev, M.H., 2012
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
NEJM 366:1099-1107, Parsons,M.,et al, 2012
Infarct Volume is a Pivotal Biomarker After Inter-Arterial Stroke Therapy
Stroke 43:1323-1330, Yoo,A.J.,et al, 2012
Bridging Therapy in Acute Ischemic Stroke
Stroke 43:1302-1308, Mazighi,M.,et al, 2012
Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score
Ann Neurol 71:634-641, Strbian,D.,et al, 2012
Selecting Stroke Patients for Intra-Arterial Therapy
Neurol 78:755-761, Balucani,C. and Grotta,J.C., 2012
Safety of Thrombolysis in Patients Over the Age of 80
The Neuroogist 18:99-101, Willey,J.Z.,et al, 2012
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
Neurological Disorders in Primary Sjogrens Syndrome
Autoimmune Dis: DOI: ID.1152012/645967, Tobon, G.J.,et al, 2012
The Diagnosis and Treatment of Limbic Encephalitis
Acta Neurol Scand 126:365-375, Asztely, F. & Kumliem, E., 2012
The Safety of Intravenous Thrombolysis for Ischemic Stroke in Patients with Pre-Existing Cerebral Aneurysms
Stroke 43:412-416, Edwards,N.J.,et al, 2012
Clincopathologic Conference,Graves Disease with Thyrotoxic Periodic Paralysis
NEJM 366:553-560, Case 4-2012, 2012
Stiff-Man Syndrome and Variants
Arch Neurol 69:230-238, McKeon,A.,et al, 2012
The Argatroban and Tissue-Type Plasminogen Activator Stroke Study
Stroke 43:770-775,623, Barreto,A.D.,et al, 2012
Does Helicopter Emergency Medical Service Transfer Offer Benefit to Patients with Stroke?
Stroke 43:878-880, Olson,M.D. and Rabinstein,A.A., 2012
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Hashimoto Encephalopathy
Neurol 78:e134, Afshari, M.,et al, 2012
Factors Influencing In-Hospital Delay in Treatment with Intravenous Thrombolysis
Stroke 43:1578-1583, Mikulik, R.,et al, 2012
Primary Sjogren Syndrome
BMJ 344:e3821, Ramos-Casals, M.,et al, 2012
The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012
Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012